Voyager Therapeutics

Voyager Therapeutics is a biotechnology company that focuses on gene therapy and next-generation adeno-associated virus (AAV) capsids to treat neurological diseases. Its pipeline is largely centered on treating central nervous system diseases such as Parkinson’s disease, amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and Huntington’s disease. The company has developed a screening platform, TRACER, which is designed to surpass the performance of conventional AAV in targeting desired cells and tissues with greater accuracy and at lower dosages. This can identify vectors that enable single-dose treatments for various diseases. Voyager is publicly held.